An interventional study of Device and app system designed for participant to self-administer Habit Reversal Training and Reminder bracelet control condition in Trichotillomania, sponsored by HabitAware Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by HabitAware Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Trichotillomania with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Trichotillomania · United States.
Among the 39 studies in Trichotillomania with a site in United States, this one is the 32nd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2020, is one of 18 with no phase, and was the 28th registered.
48 studies on the registry are indexed under Trichotillomania; 8 are open to participants now.
Browse Trichotillomania studies →5 of the 39 studies in Trichotillomania with a site in United States are open now. Recruiting first, the newest first:
HabitAware Inc. · Sites in United States
Ages 18+
HabitAware Inc. · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–65
University of Wisconsin, Milwaukee · Sites in United States
Ages 18–60
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Trichotillomania studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 2 · Phase 4 1
First in 1996; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 39 across 45 interventional studies indexed under Trichotillomania.
Median enrollment 39 across the 37 interventional studies, 734 across the 2 observational. Of the 31 that completed or were terminated, 13 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 39 have an industry lead sponsor. The 10 most frequent:
HabitAware Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
HabitAware Inc. has 3 studies filed under Trichotillomania — fewer than ten, so there is no comparison to draw.
4 of the studies in Trichotillomania with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05118633HabitAware Inc.Technology Assisted Treatment for Trichotillomania | 2026-12-31 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT05207085Yale UniversityEfficacy of Valbenazine for the Treatment of Trichotillomania in Adults | 2027-02-15 |
| NCT05377125University of Wisconsin, MilwaukeeNeural Mechanisms of Response Inhibition Training for OCRD | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 39 studies in Trichotillomania with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Trichotillomania is characterized by recurrent hair pulling resulting in hair loss causing significant distress and impairment which persists despite repeated attempts to stop. Behavioral based therapies focused on increasing awareness of hair pulling followed by the use of an incompatible behavior have proven effective. In an effort to enhance awareness, a wrist worn motion detection device was created. In this study, we will test the feasibility of the HabitAware device and accompanying app as a system for delivering self-administered habit reversal training (HRT).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group will receive the device which alerts the participant when performing hair pulling behavior and the app which provides psychoeducation and components of Habit Reversal Training.
Behavioral: Device and app system designed for participant to self-administer Habit Reversal Training
This group will receive only a device that vibrates randomly several times per hour as a reminder not to pull.
Behavioral: Reminder bracelet control condition
Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
Percentage of Participants in the HabitAware Condition That Wore the Device for 6 Hours Per Day and More Than 4 Days Per Week.
Measured via post-treatment surveys.
Time frame: Four weeks
Percentage of Participants That Reported the Device >3 on a Scale of 1-5 for Accuracy.
Measured by post treatment survey results
Time frame: Four weeks
Number of Participants That Can Implement HRT Procedures With 80% Accuracy
Measured by trained clinician observing the participant perform the procedures
Time frame: Four weeks
Number of Participants With 30% Improvement in Clinical Symptoms
Measured via pre- and post-treatment MGH-HPS (Massachusetts General Hospital Hair Pulling Scale) and/or NIMH-TSS (National Institute of Mental Health - Trichotillomania Symptom Severity) scores for those in the HabitAware conditions.
Time frame: Four weeks
| Milestone | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition |
|---|---|---|
| Started | 10 | 5 |
| Completed | 10 | 5 |
| Not completed | 0 | 0 |
Measured via post-treatment surveys.
| Participants | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition |
|---|---|---|
| Percentage of Participants in the HabitAware Condition That Wore the Device for 6 Hours Per Day and More Than 4 Days Per Week. | 9 | 0 |
Measured by post treatment survey results
| Participants | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition |
|---|---|---|
| Percentage of Participants That Reported the Device >3 on a Scale of 1-5 for Accuracy. | 10 | 0 |
Measured by trained clinician observing the participant perform the procedures
| Participants | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition |
|---|---|---|
| Number of Participants That Can Implement HRT Procedures With 80% Accuracy | 4 | 0 |
Measured via pre- and post-treatment MGH-HPS (Massachusetts General Hospital Hair Pulling Scale) and/or NIMH-TSS (National Institute of Mental Health - Trichotillomania Symptom Severity) scores for those in the HabitAware conditions.
| Participants | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition |
|---|---|---|
| Number of Participants With 30% Improvement in Clinical Symptoms | 6 | 3 |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Group - HabitAware Condition | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Control Group - Reminder Bracelet Condition | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Continuous(years) | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition | Total |
|---|---|---|---|
| Mean | 39.5 ± 15.5 | 31.2 ± 7.6 | 36.7 ± 13.7 |
| Sex: Female, Male(Participants) | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition | Total |
|---|---|---|---|
| Female | 10 | 5 | 15 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Experimental Group - HabitAware Condition | Control Group - Reminder Bracelet Condition | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 5 | 13 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Mar 2020, 1 month.
Results were first posted in Mar 2023, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HabitAware Inc.